Condition (MeSH)
Nephrogenic Fibrosing Dermopathy
ClinicalTrials.gov lists 10 trials for Nephrogenic Fibrosing Dermopathy or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
10 of the 10 trials are tagged with Nephrogenic Fibrosing Dermopathy itself; the rest are tagged with a narrower condition beneath it.
When did Nephrogenic Fibrosing Dermopathy trials start? (5)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2021 | 1 |
| 2009 | 5 |
| 2008 | 1 |
| 2007 | 2 |
| 2002 | 1 |
No forecast is made for this condition: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 10 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Nephrogenic Fibrosing Dermopathy trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 1 |
| Phase 2/3 | 1 |
| Phase 3 | 1 |
| Phase 4 | 3 |
| Observational | 4 |
How many Nephrogenic Fibrosing Dermopathy trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Completed | 6 |
| Terminated | 1 |
| Withdrawn | 1 |
| Unknown status | 2 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Nephrogenic Fibrosing Dermopathy trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Bayer | 1 |
| Guerbet | 1 |
| Lantheus Medical Imaging | 1 |
Which drugs are being tested for Nephrogenic Fibrosing Dermopathy? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Imatinib | 2 |
| Gadodiamide | 1 |
| Gadoxetate Disodium | 1 |
| Vasovist | 1 |
Interventions as named in the registry (3)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Plasmapheresis | 1 |
| gadollinum | 1 |
| Gadoteric Acid Meglumine Salt | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Nephrogenic Fibrosing Dermopathy trials report? (1)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Basal cell carcinoma | 1 | 1 |
Which publications cover Nephrogenic Fibrosing Dermopathy? (23)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Gadolinium-based contrast agents: A comprehensive risk assessment. | Journal of magnetic resonance imaging : JMRI | 2017 | Yes |
| European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis. | Journal of the European Academy of Dermatology and Venereology : JEADV | 2017 | Yes |
| Gadolinium-Induced Fibrosis. | Annual review of medicine | 2016 | Yes |
| Treatment of Skin Calcifications with Intra-lesional Injection of Sodium Thiosulphate: A Case Series. | Acta dermato-venereologica | 2016 | Yes |
| Gadolinium-based compounds induce NLRP3-dependent IL-1β production and peritoneal inflammation. | Annals of the rheumatic diseases | 2015 | Yes |
Showing 5 of 23 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.